A single centre experience in challenging diagnosis and management of osseous and extraosseous Ewing sarcoma: a case series
DOI:
https://doi.org/10.18203/2349-3933.ijam20252533Keywords:
Ewing sarcoma, Bone, Incidence, Early detection, IHCAbstract
Ewing sarcoma (ES) predominantly affects adolescents and young adults, commonly involving the pelvis, femur, and chest wall. This case series analysed the clinicopathological features and treatment profiles of 12 pediatric and adolescent ES patients treated at Tirunelveli Medical College Hospital, Tamil Nadu, from 2019 to 2023. The peak incidence occurred in the 6–15-year age group, with a female predominance. Osseous ES was the most common subtype, with most patients presenting with localised disease or lung metastases. Treatment included chemotherapy, surgery, and radiotherapy, delivered through a multidisciplinary approach. Survival outcomes varied based on disease extent and response to treatment. Advances in radiotherapy and surgical management of oligometastatic disease, along with multiple chemotherapy cycles, may enhance prognosis. The study highlights the importance of early detection, increased awareness, and structured follow-up protocols in improving outcomes. Tailored, comprehensive management strategies are crucial for addressing the clinical challenges of ES in resource-limited settings.
Metrics
References
Durer S, Gasalberti DP, Shaikh H. Ewing sarcoma. StatPearls, Treasure Island (FL): StatPearls Publishing. 2024.
Raney RB, Asmar L, Newton WA, Bagwell C, Breneman JC, Crist W, et al. Ewing’s sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol. 1997;15:574–82. DOI: https://doi.org/10.1200/JCO.1997.15.2.574
Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett. 2007;254:1–10. DOI: https://doi.org/10.1016/j.canlet.2006.12.009
Worch J, Ranft A, DuBois SG, Paulussen M, Juergens H, Dirksen U. Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. Pediatr Blood Cancer. 2018;65:27532. DOI: https://doi.org/10.1002/pbc.27251
Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol. 2003;21:3423–30. DOI: https://doi.org/10.1200/JCO.2003.10.033
Muralidhar D, Vasugi GA, Sundaram S. Incidence and demographic profile of Ewings sarcoma: Experience from a tertiary care hospital. Cureus. 2021;13:18339. DOI: https://doi.org/10.7759/cureus.18339
Chinchilla-Tábora LM, Ortiz Rodríguez-Parets J, González Morais I, Sayagués JM, Ludeña de la Cruz MD. Immunohistochemical analysis of CD99 and PAX8 in a series of 15 molecularly confirmed cases of Ewing sarcoma. Sarcoma 2020;2:3180798. DOI: https://doi.org/10.1155/2020/3180798
Ghandour M, Lehner B, Klotz M, Geisbüsch A, Bollmann J, Renkawitz T, et al. Extraosseous Ewing sarcoma in children: A systematic review and meta-analysis of clinicodemographic characteristics. Children (Basel). 2022;9:47. DOI: https://doi.org/10.3390/children9121859
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701. DOI: https://doi.org/10.1056/NEJMoa020890
Pretz JL, Barysauskas CM, George S, Hornick JL, Raut CP, Chen YLE, et al. Localized adult Ewing sarcoma: Favorable outcomes with alternating vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide (VDC/IE)-based multimodality therapy. Oncologist. 2017;22:1265–70. DOI: https://doi.org/10.1634/theoncologist.2016-0463